Cibus (CBUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 2, 2026, with voting on director elections, executive compensation, and auditor ratification.
Stockholders of record as of April 6, 2026, are entitled to vote; each share of Class A Common Stock has one vote.
Proxy materials are primarily distributed online to improve efficiency and reduce costs.
Voting matters and shareholder proposals
Stockholders will vote on electing nine directors, approving executive compensation on an advisory basis, and ratifying BDO USA, P.C. as the independent auditor for 2026.
Board recommends voting FOR all proposals.
Procedures for submitting proposals and director nominees for the 2027 meeting are detailed, with deadlines and requirements for compliance with SEC rules.
Board of directors and corporate governance
Board will reduce from ten to nine members after the meeting; seven of nine will be independent.
Leadership structure separates CEO and Chairman roles; independence is periodically reviewed.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Strategy, each with defined responsibilities and charters.
Board and committees met regularly in 2025, with high attendance.
Corporate Governance Guidelines and Code of Business Conduct and Ethics are in place and reviewed annually.
Latest events from Cibus
- 36% revenue growth, narrowed losses, and regulatory wins, but more capital is needed.CBUS
Q2 2026 - Gene editing accelerates crop innovation and royalty growth as global regulatory support expands.CBUS
LD Micro Main Event XIX Investor Conference - EU regulatory shift accelerates gene editing commercialization and royalty growth prospects.CBUS
Sidoti Small-Cap Virtual Investor Conference - Directors re-elected, executive pay approved, and auditor ratified with no shareholder questions.CBUS
AGM 2026 - Biotech firm targets $200M in offerings amid liquidity concerns and potential shareholder dilution.CBUS
Registration filing - Revenue up, net loss down, and cash funds operations into late Q1 2027; more capital needed.CBUS
Q1 2026 - Key votes include director elections, executive pay approval, and auditor ratification for 2026.CBUS
Proxy filing - Q3 net loss of $201.5M from goodwill impairment; cost savings and commercialization ongoing.CBUS
Q3 2024 - Gene editing is transforming agriculture with rapid regulatory acceptance and high-margin royalty models.CBUS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024